Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Raj Patel

Internal Medicine Schaumburg, IL Medical Doctor

NPI 1093004459 CMS profile 536560

800 E Woodfield Rd, Suite 102, Schaumburg, IL 60173

Open in the dashboard

General payments

$13,332

627 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raj Patel of Schaumburg, IL is reported in the CMS Open Payments database as having received $13,332 across 627 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,323 91
2024 General $2,509 118
2023 General $1,990 103
2022 General $1,880 93
2021 General $2,402 101
2020 General $1,322 73
2019 General $906 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raj Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Raj Patel were reported at $2,323. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Raj Patel Internal Medicine median Middle half National median
2019 $906 $159 $48–$570 $163
2020 $1,322 $119 $33–$402 $114
2021 $2,402 $135 $37–$521 $132
2022 $1,880 $141 $42–$496 $149
2023 $1,990 $149 $45–$519 $160
2024 $2,509 $154 $47–$537 $164
2025 $2,323 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,014 69 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,294 84 payments
  3. Lilly USA, LLC $1,264 71 payments
  4. GlaxoSmithKline, LLC. $1,066 70 payments
  5. Painteq LLC $808 2 payments
  6. Pfizer Inc. $738 43 payments
  7. Janssen Pharmaceuticals, Inc $589 39 payments
  8. Novo Nordisk Inc $478 26 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $453 22 payments
  10. Amgen Inc. $448 31 payments
  11. Other $4,179 170 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,002 624 payments
  2. Education $285 2 payments
  3. Consulting Fee $45 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $1,576 45 payments
  2. TRELEGY ELLIPTA $914 61 payments
  3. PAINTEQ $808 2 payments
  4. JARDIANCE Diabetes $743 55 payments
  5. ZENPEP $665 20 payments
  6. MOUNJARO $584 29 payments
  7. XARELTO $551 38 payments
  8. JARDIANCE Diabetes $487 31 payments
  9. BREZTRI $465 12 payments
  10. Kerendia $453 22 payments
  11. Other $9,644 487 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 118 drugs

Part D claims

6,385

Median for Internal Medicine: 777

Drug cost

$1,588,302

Median for Internal Medicine: $73,373

Branded share of claims

22%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 51 $321,376
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 50 $273,545
Humira(Cf) Pen Adalimumab Brand 11 $151,864
Jardiance Empagliflozin Brand 123 $133,626
Trulicity Dulaglutide Brand 80 $102,785
Farxiga Dapagliflozin Propanediol Brand 85 $94,117
Januvia Sitagliptin Phosphate Brand 85 $83,164
Ozempic Semaglutide Brand 51 $60,418
Mounjaro Tirzepatide Brand 50 $59,595
Eliquis Apixaban Brand 54 $54,870

The 10 drugs with the highest cost, of 118 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$112,363

Of which drugs: $4,094

Medicare patients

266

Average age 73

Services billed

2,535

137 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%
Arthritis 50%
Ischemic heart disease 44%
Chronic kidney disease 27%
Heart failure 23%
Osteoporosis 23%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 37 37 $1,324
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 13 18 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $388
$388 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $246
  • Lilly USA, LLC $77
$322 123 —
Korlym
  • Corcept Therapeutics $177
$177 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $158
$158 85 —
MOUNJARO
  • Lilly USA, LLC $131
$131 50 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

627 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record